Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acne Vulgaris pipeline constitutes 20+ key companies continuously working towards developing 22+ Acne Vulgaris treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acne Vulgaris Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Acne Vulgaris Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acne Vulgaris Market.

Some of the key takeaways from the Acne Vulgaris Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Acne Vulgaris treatment therapies with a considerable amount of success over the years.

*
Acne Vulgaris companies working in the treatment market are BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others, are developing therapies for the Acne Vulgaris treatment

*
Emerging Acne Vulgaris therapies in the different phases of clinical trials are - BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF Registered , Imsidolimab, RA-18C3, FMX101, IDP-126, and others are expected to have a significant impact on the Acne Vulgaris market in the coming years.

*
In July 2024, Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW), a late-stage biotechnology company focused on treating medical and aesthetic skin conditions, announced that it has successfully enrolled 50% of patients in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study. This study evaluates DMT310, a novel, once-weekly topical treatment for moderate-to-severe acne. The STAR-1 study is the first of two Phase 3 trials that, if successful, will support the Company's filing of a new drug application (NDA) for DMT310 to treat moderate-to-severe acne.

*
In December 2023, Dermata Therapeutics has initiated enrollment of the initial participant in the Phase III STAR-1 clinical trial of DMT310, its topical product candidate for treating moderate-to-severe acne. STAR-1 marks the first of two Phase III studies in the DMT310 clinical program designed to evaluate the safety, effectiveness, and tolerance of the product for individuals with facial acne. This trial, conducted under double-blind, placebo-controlled conditions, will randomize participants aged nine years and older in the United States and Latin America at a ratio of 2:1 to receive either DMT310 or a placebo.

*
In December 2023, Ascletis Pharma has initiated a Phase III clinical trial for ASC40 (Denifanstat), its drug candidate aimed at treating moderate to severe acne vulgaris in China. This multicenter, double-blind, randomized, and placebo-controlled trial aims to evaluate the effectiveness and safety of ASC40. The study plans to enroll 480 participants who will be randomly assigned in a 1:1 ratio to receive either a daily oral dose of 50mg of ASC40 or a placebo over a period of 12 weeks.

Acne Vulgaris Overview

Acne vulgaris, commonly referred to as acne, is a chronic inflammatory skin condition that primarily affects the face, neck, chest, back, and shoulders. It is characterized by the formation of comedones (such as blackheads and whiteheads), papules, pustules, nodules, and occasionally cysts.

Get a Free Sample PDF Report to know more about Acne Vulgaris Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight [https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Acne Vulgaris Drugs Under Different Phases of Clinical Development Include:

*
BPX-01: BioPharmX

*
IDP-120: Bausch Health Americas, Inc.

*
GT20029: Kintor Pharma

*
KX-826: KintorPharma

*
S6G5T-3: Sol-Gel Technologies, Ltd.

*
ASC40: Ascletis Pharma

*
GK530G: Galderma R&D

*
Dapsone: Torrent Pharma

*
DMT310: Dermata Therapeutics

*
CD5789 (trifarotene): Galderma R&D

*
Afamelanotide: Clinuvel Pharma

*
NVN1000: Novan, Inc.

*
Hydrogen Peroxide: Dermata Therapeutics

*
Trifarotene Cream: Galderma R&D

*
S6G5T-3: Accelovance

*
GDC 268 Lotion: Balmoral Medical

*
Isotretinoin: Vyne Therapeutics Inc.

*
gevokizumab: XOMA (US) LLC

*
BLI1100: Braintree Laboratories

*
AKLIEF Registered : Teva Pharma

*
Imsidolimab: AnaptysBio, Inc.

*
RA-18C3: Janssen Research

*
FMX101: Cutia Therapeutics

*
IDP-126: Bausch Health

Acne Vulgaris Route of Administration

Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravitreal

*
Subretinal

*
Topical

Acne Vulgaris Molecule Type

Acne Vulgaris Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

Acne Vulgaris Pipeline Therapeutics Assessment

*
Acne Vulgaris Assessment by Product Type

*
Acne Vulgaris By Stage and Product Type

*
Acne Vulgaris Assessment by Route of Administration

*
Acne Vulgaris By Stage and Route of Administration

*
Acne Vulgaris Assessment by Molecule Type

*
Acne Vulgaris by Stage and Molecule Type

DelveInsight's Acne Vulgaris Report covers around 16+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Acne Vulgaris product details are provided in the report. Download the Acne Vulgaris pipeline report to learn more about the emerging Acne Vulgaris therapies [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Acne Vulgaris Therapeutics Market include:

Key companies developing therapies for Acne Vulgaris are - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation, Galderma SA, Bausch Health Companies Inc, Taro Pharmaceutical Industries Ltd, Tehran University of Medical Sciences, Hamedan University of Medical Sciences, and others.

Acne Vulgaris Pipeline Analysis:

The Acne Vulgaris pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.

*
Acne Vulgaris key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acne Vulgaris drugs and therapies [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acne Vulgaris Pipeline Market Drivers

*
High Prevalence, Growing Awareness, Advances in Research, Technological Innovations, Demand for Safer and Effective Treatments, Regulatory Support, are some of the important factors that are fueling the Acne Vulgaris Market.

Acne Vulgaris Pipeline Market Barriers

*
However, Complex Disease Mechanisms, Efficacy Challenges, Safety Concerns, High Development Costs, Competitive Landscape, Patient Compliance and other factors are creating obstacles in the Acne Vulgaris Market growth.

Scope of Acne Vulgaris Pipeline Drug Insight

*
Coverage: Global

*
Key Acne Vulgaris Companies: BioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies, Ltd., Ascletis Pharma, Galderma R&D, Torrent Pharma, Dermata Therapeutics, Clinuvel Pharma, Novan, Inc., Dermata Therapeutics, Accelovance, Balmoral Medical, Vyne Therapeutics Inc., XOMA (US) LLC, Braintree Laboratories, Teva Pharma, AnaptysBio, Inc., Janssen Research, Cutia Therapeutics, Bausch Health, and others

*
Key Acne Vulgaris Therapies: BPX-01, IDP-120, GT20029, KX-826, S6G5T-3, ASC40, GK530G, Dapsone, DMT310, CD5789 (trifarotene), Afamelanotide, NVN1000, Hydrogen Peroxide, Trifarotene Cream, S6G5T-3, GDC 268 Lotion, Isotretinoin, gevokizumab, BLI1100, AKLIEF Registered , Imsidolimab, RA-18C3, FMX101, IDP-126, and others

*
Acne Vulgaris Therapeutic Assessment: Acne Vulgaris current marketed and Acne Vulgaris emerging therapies

*
Acne Vulgaris Market Dynamics: Acne Vulgaris market drivers and Acne Vulgaris market barriers

Request for Sample PDF Report for Acne Vulgaris Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acne Vulgaris Report Introduction

2. Acne Vulgaris Executive Summary

3. Acne Vulgaris Overview

4. Acne Vulgaris- Analytical Perspective In-depth Commercial Assessment

5. Acne Vulgaris Pipeline Therapeutics

6. Acne Vulgaris Late Stage Products (Phase II/III)

7. Acne Vulgaris Mid Stage Products (Phase II)

8. Acne Vulgaris Early Stage Products (Phase I)

9. Acne Vulgaris Preclinical Stage Products

10. Acne Vulgaris Therapeutics Assessment

11. Acne Vulgaris Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acne Vulgaris Key Companies

14. Acne Vulgaris Key Products

15. Acne Vulgaris Unmet Needs

16 . Acne Vulgaris Market Drivers and Barriers

17. Acne Vulgaris Future Perspectives and Conclusion

18. Acne Vulgaris Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acne-vulgaris-pipeline-update-2024-fda-approvals-therapeutic-advancements-moa-roa-by-delveinsight-dermata-therapeutics-astrazeneca-novartis-ucb-pharma-incyte-inc-galderma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.